Consensus Lantern Pharma Inc.

Equities

LTRN

US51654W1018

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
6.16 ^USD	-9.54%		+0.16%	+43.93%

May. 09	Transcript : Lantern Pharma Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Lantern Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Lantern Pharma Inc.

Price target over the last 5 years

History of analyst recommendation changes

62de8f531ca4530eada280532.WBCw4TrywWTXywQqGKP_fYEGFhoIiwJ2uvBwAuD13P0.KmXas2ykuA29hzZjVfe0LMM2bk1s-DQA-J4hSbatmacePeGtF4S5Se6iYw~1e78bbe3f9ab8ba0df6f917641abab9c

Analyst Recommendations on Lantern Pharma Inc.

HC Wainwright Starts Lantern Pharma at Neutral	23-05-18	MT
EF Hutton Starts Lantern Pharma at Buy With $11 Price Target	22-11-01	MT
HC Wainwright Adjusts Lantern Pharma's Price Target to $36 From $34, Reiterates Buy Rating	22-03-11	MT
HC Wainwright Adjusts Lantern Pharma's Price Target to $34 From $32, Keeps Buy Rating	21-11-02	MT
LANTERN PHARMA : HC Wainwright Starts Lantern Pharma at Buy with $32 Price Target	21-10-07	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.16 USD

Average target price

22 USD

Spread / Average Target

+257.14%

High Price Target

26 USD

Spread / Highest target

+322.08%

Low Price Target

18 USD

Spread / Lowest Target

+192.21%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Lantern Pharma Inc.

HC Wainwright
EF Hutton

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar